Institutional Shareholder Services Inc. ("ISS") Recommends OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction - Seite 2

“The dissident's alternate financing proposal, released on Dec. 20, 2019, lacks substance. There is no mention of potential valuation or terms, and no evidence that the dissident has the ability to provide or raise the promised financing.”

President and Chief Executive Officer of OncoSec, Daniel J. O’Connor, commented on the report: “We are pleased with ISS’ conclusion that the CGP/Sirtex Transaction is the best path forward for OncoSec. Notably, the ISS analysis supports what we have said all along: OncoSec reviewed all available alternatives, the need for this financing is urgent and the claims Alpha has been making in its effort to block the CGP/Sirtex Transaction are simply without merit or credibility. We are confident this partnership will deliver the best outcome for all shareholders and allow OncoSec to see its two clinical trials to completion. We urge shareholders to vote FOR the CGP/Sirtex Transaction on the WHITE proxy card to ensure the future success of OncoSec.”

OncoSec, like ISS, recommends shareholders vote "FOR" the CGP/Sirtex Transaction on the WHITE proxy card today.

Additional information about the CGP/Sirtex Transaction and how to vote can be found at https://advancingoncosec.com/.

If you have any questions on how to vote, please contact the Company’s proxy solicitor at the contact listed below:

MORROW
SODALI

509 Madison Avenue, Suite 1608
New York, NY 10022
Stockholders Call Toll Free: [phone]
E-mail: [e-mail]

About CGP

CGP is a public company listed on the Hong Kong stock exchange with a market capitalization of approximately $1.8 billion USD. CGP develops, manufactures and distributes pharmaceutical products and medical devices to retailers and medical organizations. CGP currently distributes its products to approximately 6,000 hospitals and approximately 30,000 pharmacies and has a sales team of more than 2,000 employees. CGP also has significant experience in R&D and product commercialization in China. Such experience dealing with the relevant Chinese regulatory bodies makes CGP an ideal strategic partner for OncoSec as it looks to gain regulatory approval to introduce TAVO to the Chinese market. For more information, visit www.chinagrandpharm.com.